| Outcome Measures: |
Primary: Change in renal perfusion, The change in renal perfusion measured by ASL-MRI Scanning, 20 weeks | Secondary: Change in cardiac function, The change in cardiac function measured by cardiac MRI scanning, 20 weeks|Change in cerebral perfusion, The change in cerebral perfusion measured by cerebral ASL MRI, 20 weeks|Change in haemodynamic variables, The change in the following haemodynamic variables: non-invasive measurement of cardiac output, heart rate, blood pressure and baroreflex sensitivity, 20 weeks|Change in arterial stiffness, The change in arterial stiffness measured using cartoi-femoral Pulsewave Velocity Assessment and Augmentation Index, 20 weeks|Change in body composition, The change in body composition measured using Bioelectrical Impedance Analysis, 20 weeks|Number of participants with adverse events and serious adverse events, 20 weeks|Plasma concentration of bardoxolone methyl, 20 weeks|Change in cerebral white matter microstructure, 20 weeks|Change in total body water, The change in total body water measured using Bioelectrical Impedance Analysis, 20 weeks
|
